Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction

NCT04939246 · View on ClinicalTrials.gov ↗

Study Summary

This is a multi-site single arm feasibility study of single-fraction Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph node, pancreas, and/or kidney. Stereotactic ablative body radiation therapy (SABR) is a highly-focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.

Conditions Studied

Interventions

  • RADIATION Stereotactic ablative body radiation therapy

Study Locations (2)

Florida

  • Miami Cancer Institute at Baptist Health South Florida — Miami

Wisconsin

  • University of Wisconsin Hospital and Clinics — Madison

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-06-18
Est. Completion 2024-07-17
Phase NA

Sponsor

Baptist Health South Florida

82 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04939246

The ClinicalTrials.gov registry entry for NCT04939246 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baptist Health South Florida, which has 82 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Metastatic Carcinoma appearing as the primary indexed condition, and to 1 intervention — of which Stereotactic ablative body radiation therapy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04939246 reports 2 study locations spanning 2 distinct geographic areas — top geographies include Florida, Wisconsin. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04939246 about?

NCT04939246 is a clinical study titled "Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction". This is a multi-site single arm feasibility study of single-fraction Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph node, pancreas, and/or kidney. Stereotactic ablative body radiation the...

What is the current status of trial NCT04939246?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-06-18. Estimated completion is 2024-07-17.

What conditions does trial NCT04939246 study?

This clinical trial studies the following conditions: Metastatic Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04939246?

The interventions under investigation include: Stereotactic ablative body radiation therapy (RADIATION). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04939246?

This trial is sponsored by Baptist Health South Florida, which has 82 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04939246 being conducted?

This trial has 2 study locations across Florida, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial